Compare ETS & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETS | APVO |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 8.3M |
| IPO Year | 2025 | N/A |
| Metric | ETS | APVO |
|---|---|---|
| Price | $0.53 | $8.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 83.3K | ★ 407.4K |
| Earning Date | 04-14-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,585,885.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.59 | N/A |
| 52 Week Low | $0.49 | $7.66 |
| 52 Week High | $4.23 | $1,688.40 |
| Indicator | ETS | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 59.76 |
| Support Level | $0.52 | $8.49 |
| Resistance Level | $0.58 | $9.11 |
| Average True Range (ATR) | 0.03 | 0.83 |
| MACD | 0.00 | -0.29 |
| Stochastic Oscillator | 38.07 | 18.09 |
Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients' doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable, and innovative delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.